DE69310182D1 - Interleukin-4 stimulierter t-lymphozyten-zelltod - Google Patents

Interleukin-4 stimulierter t-lymphozyten-zelltod

Info

Publication number
DE69310182D1
DE69310182D1 DE69310182T DE69310182T DE69310182D1 DE 69310182 D1 DE69310182 D1 DE 69310182D1 DE 69310182 T DE69310182 T DE 69310182T DE 69310182 T DE69310182 T DE 69310182T DE 69310182 D1 DE69310182 D1 DE 69310182D1
Authority
DE
Germany
Prior art keywords
interleukin
population
stimulated
cell death
lymphocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69310182T
Other languages
English (en)
Other versions
DE69310182T2 (de
Inventor
Michael Lenardo
Stefen Boehme
Jeffrey Critchfield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of DE69310182D1 publication Critical patent/DE69310182D1/de
Application granted granted Critical
Publication of DE69310182T2 publication Critical patent/DE69310182T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69310182T 1992-08-10 1993-08-10 Interleukin-4 stimulierter t-lymphozyten-zelltod Expired - Lifetime DE69310182T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92629092A 1992-08-10 1992-08-10
PCT/US1993/007471 WO1994003202A1 (en) 1992-08-10 1993-08-10 Interleukin-4 stimulated t lymphocyte cell death

Publications (2)

Publication Number Publication Date
DE69310182D1 true DE69310182D1 (de) 1997-05-28
DE69310182T2 DE69310182T2 (de) 1997-12-04

Family

ID=25453003

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69310182T Expired - Lifetime DE69310182T2 (de) 1992-08-10 1993-08-10 Interleukin-4 stimulierter t-lymphozyten-zelltod

Country Status (8)

Country Link
US (1) US5935575A (de)
EP (1) EP0655927B1 (de)
JP (2) JP3982588B2 (de)
AT (1) ATE151989T1 (de)
AU (1) AU688736B2 (de)
CA (1) CA2140878C (de)
DE (1) DE69310182T2 (de)
WO (1) WO1994003202A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003202A1 (en) * 1992-08-10 1994-02-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Interleukin-4 stimulated t lymphocyte cell death
AU699217B2 (en) * 1993-06-09 1998-11-26 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Interleukin-2 stimulated T lymphocyte cell death for the treatment of autoimmune diseases, allergic disorders, and graft rejection
AU768571B2 (en) * 1994-06-03 2003-12-18 Dana-Farber Cancer Institute Ligands for induction of antigen specific apoptosis in T cells
US6719972B1 (en) 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
AU2004201139C1 (en) * 1994-06-03 2008-06-12 Dana-Faber Cancer Institute Ligands for induction of antigen specific apoptosis in T cells
US7041503B2 (en) 1995-05-02 2006-05-09 The United States Of America As Represented By The Department Of Health And Human Services Modified myelin basic protein molecules
EP0914163B1 (de) * 1997-02-28 2016-02-24 Enzo Therapeutics, Inc. Verfahren zur selektiven Immunherabregulation (SIDR)
WO1999051247A1 (en) * 1998-04-03 1999-10-14 Osiris Therapeutics, Inc. Use of human mesenchymal stem cells to induce t-cell apoptosis
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US20030170258A1 (en) * 2001-05-09 2003-09-11 Enzo Therapeutics, Inc. Novel processes implementing selective immune down regulation (SIDR)
US20050084967A1 (en) * 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20040175373A1 (en) * 2002-06-28 2004-09-09 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
EP1539929B1 (de) * 2002-06-28 2013-04-10 Life Technologies Corporation Verfahren zur wiederherstellung des immunrepertoirs in patienten mit immunologischen defekten in verbindung mit autoimmunität sowie transplantation von organen oder hämatopoetischen stammzellen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904481A (en) * 1985-04-17 1990-02-27 The Board Of Trustess Of Leland Stanford University Method of conferring immuno-tolerance to a specific antigen
DE69018990T2 (de) * 1989-07-14 1995-12-14 Praxis Biolog Inc Stabile interleukine enthaltende impfstoffzusammensetzungen.
EP0563254B1 (de) * 1990-12-19 1995-11-08 Schering Corporation Anwendung von il-4 zur steigerung der immunantwort auf immunogene in impfstoffen
WO1994003202A1 (en) * 1992-08-10 1994-02-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Interleukin-4 stimulated t lymphocyte cell death

Also Published As

Publication number Publication date
CA2140878C (en) 2007-12-04
DE69310182T2 (de) 1997-12-04
JP3982588B2 (ja) 2007-09-26
AU4805293A (en) 1994-03-03
JPH07509724A (ja) 1995-10-26
CA2140878A1 (en) 1994-02-17
US5935575A (en) 1999-08-10
JP2007077164A (ja) 2007-03-29
WO1994003202A1 (en) 1994-02-17
AU688736B2 (en) 1998-03-19
EP0655927B1 (de) 1997-04-23
EP0655927A1 (de) 1995-06-07
ATE151989T1 (de) 1997-05-15

Similar Documents

Publication Publication Date Title
DE69310182D1 (de) Interleukin-4 stimulierter t-lymphozyten-zelltod
DE69839992D1 (de) Vorbeugende- oder Heilmittel zur Behandlung von Multipler Sklerose, mit antagonistischen anti-IL6-Rezeptor Antikörpern als Wirkstoff
DE69621918D1 (de) Medikamente zur behandlung von autoimmunerkrankungen mit interferon-tau
ATE224753T1 (de) Vorrichtung zur verabreichung von medikamenten durch elektrotransport
DE69840025D1 (de) Assoziierter antworten
DK0499939T3 (da) Ladesystem til implanterbare høreapparater og Tinnitus-maskerere
MXPA02001911A (es) Anticuerpos ctla-4 humanos y sus usos.
DK1005358T3 (da) Anvendelse af et neurturinprotein-produkt til forebyggelse og behandling af hørenedsættelse
EP0526544A4 (en) Therapeutic uses of actin-binding compounds
DE69410254T2 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
NO972391D0 (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
FR2379286A1 (fr) Compositions anti-tumorales a base d'homopolymeres ou de copolymeres hydrosolubles
FR2700472B1 (fr) Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2.
HUP9802091A2 (hu) Idegátültetés pluripotens neuroepiteliális sejtek alkalmazásával
US4873609A (en) Portable electronic unit for treatment of bites by poisonous snakes or other animals or allergic contracts
DK0841939T3 (da) Terapeutiske midler og autoimmune sygdomme
MX9301789A (es) Nuevos oligopeptidos lipofilicos con actividad inmunomoduladora.
NO964199L (no) Behandling av autoimmun sykdom ved anvendelse av oral tolerisering og/eller type I interferon
Todt et al. Down‐regulation of interleukin‐12, interleukin‐12R expression/activity mediates the switch from Th1 to Th2 granuloma response during murine Schistosomiasis mansoni
BG102404A (en) The application of flupirtin for the prevention and treatment of diseases related to impairement of the haematopoeic cellular system
MX9407876A (es) Formulaciones de hongos entomopatogenos para uso como insecticidas biologicos.
IL105498A0 (en) Pharmaceutical composition containing ribonucleotide polymerase
MX9203054A (es) Charola de anzuelo de gran actividad para cucarachas
DE69724767D1 (de) Pestizid das einen photosensibilisator und einen lockstoff enthält
NO930406L (no) Spesifikke antistoffer mot aktiverte blodplater samt fremstilling derav

Legal Events

Date Code Title Description
8364 No opposition during term of opposition